Benjamin Zeskind Acquires 2,400 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin Zeskind bought 2,400 shares of the stock in a transaction on Tuesday, June 23rd. The shares were bought at an average price of $4.56 per share, for a total transaction of $10,944.00. Following the purchase, the chief executive officer directly owned 2,315,252 shares in the company, valued at approximately $10,557,549.12. This trade represents a 0.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Immuneering Stock Down 1.5%

IMRX opened at $4.53 on Friday. The stock has a market capitalization of $293.09 million, a price-to-earnings ratio of -3.87 and a beta of 0.38. The firm has a 50 day moving average price of $4.97 and a 200-day moving average price of $5.24. Immuneering Corporation has a twelve month low of $2.90 and a twelve month high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. As a group, analysts expect that Immuneering Corporation will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Immuneering

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Immuneering in the first quarter worth about $32,000. Geode Capital Management LLC grew its stake in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after acquiring an additional 4,458 shares in the last quarter. XTX Topco Ltd bought a new position in Immuneering in the 2nd quarter worth about $90,000. Bridgeway Capital Management LLC increased its position in shares of Immuneering by 57.9% during the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after acquiring an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in shares of Immuneering during the second quarter valued at approximately $215,000. 67.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research report on Monday, March 9th. Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.